Lupus

SCOTTSDALE, Ariz. — A novel therapeutic approach targeting the neonatal fragment crystallizable receptor may have implications across a number of rheumatology disease states, according to a speaker.

SCOTTSDALE, Ariz. — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.

In this video, Audra Horomanski, MD, discusses highlights in vasculitis treatment and management from recent conferences.

Apoptotic lymphocytes in peripheral blood may be a meaningful factor in the prognosis of juvenile-onset systemic lupus erythematosus, as well as a predictor of disease activity, according to data published in Pediatric Rheumatology.

Kidney Disease: Improving Global Outcomes has released a revised clinical practice guideline for the treatment of lupus nephritis.

Hispanic patients with systemic sclerosis are more likely to have concurrent systemic lupus erythematosus and U1-RNP positivity, and face greater mortality rates vs. non-Hispanic white patients, according to data.

Depression and physical function should be assessed at least once per year in all patients with systemic lupus erythematosus, according to recommended quality measures devised by an American College of Rheumatology workgroup.

This month’s cover story analyzes a serious problem, namely the underrepresentation of patients from marginalized communities in lupus clinical trials.

The body of data demonstrating that lupus significantly and disproportionately impacts Black, Hispanic and Asian patients is robust. It should therefore follow that these populations are appropriately represented in clinical trials for the disease.

Black patients have a three- to five-fold increased incidence of primary chronic cutaneous lupus vs. white patients, but are often completely missing from training materials and most images of cutaneous lupus rashes online.